Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lab21 announces Myconostica acquisition

Lab21 announces Myconostica acquisition

24th May 2011

Lab21 has agreed a deal to acquire the molecular diagnostic company Myconostica for an undisclosed fee.

The newly-acquired firm specialises in the diagnosis of fungal infections of clinical importance, an increasingly important market in which Myconostica is an industry leader.

By purchasing the company, Lab21 will be able to add new proprietary diagnostics and nucleic acid-based assay products to its portfolio, as well as offering Myconostica fungal testing services from its laboratories in the UK and US.

This represents Lab21's sixth acquisition in the last two years and will help to strengthen its position as a key player in the diagnostics sector.

Graham Mullis, chief executive officer of Lab21, said: "The company's products complement our infectious diseases portfolio and help position the company in a large market where there are significant clinical challenges."

This comes after Lab21 assumed ownership of the UK-based diagnostics and microbiological assay specialist Microgen Bioproducts at the beginning of the year.ADNFCR-8000103-ID-800555024-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.